Skip to main content

Houston Primed for Life Sciences Boom

Published May 17, 2023 by Javier Vargas

Lab workers at TMC Houston lab

The life sciences industry is a global force driving medical innovation and advancements in health care. From pharmaceuticals and biotechnology to medical devices and diagnostics, this sector plays a crucial role in improving the quality of life for people around the world. As the industry continues to grow and evolve, new hubs of innovation are emerging, each with its unique strengths and advantages. 

Houston is a world-class region with a thriving innovation economy. With a high concentration of employment, healthy funding scene, and unwavering commitment to translational research, the Houston region has positioned itself as one of the country's fastest-growing life sciences ecosystems - ranking #13 in a 2022 CBRE industry study. Bright scientific minds, entrepreneurial drive and an active investment community gives companies fertile ground for disruptive innovation in biotech and life sciences. 

The Texas Medical Center (TMC), the world's largest medical district, offers companies a unique opportunity to collaborate and implement technology in one of the largest healthcare ecosystems. TMC and the variety of research institutions and innovative companies who operate in Houston are taking on the greatest medical challenges of our generation. 

Houston is home to over 1,700 life sciences and health care companies and establishments, making it a top-15 market for life sciences employment nationwide and first in Texas. This robust and diverse workforce, coupled with an extensive education infrastructure and world-class research institutions, makes Houston a prime location to support growth across key subsectors like cell and gene therapy manufacturing, molecular diagnostics, and biologics drug development and manufacturing. 

In addition to established companies, Houston has a vibrant startup ecosystem that provides support and resources for early-stage companies. The city has several startup incubators and accelerators, including TMCx, which is located within the Texas Medical Center and provides startups with access to mentors, funding, and other resources. TMCx has hosted over 300 companies with over $5.8 billion raised. Additionally, Houston has a strong network of angel investors and venture capitalists that are actively seeking out innovative life sciences companies to invest in. 

With the densest patient population in the world, Houston allows for transformational clinical applications. The region ranks second in the nation in clinical trial volume, with 4,906 active clinical trials in 2022, representing over 20 percent of all active U.S. trials. Companies located in Houston can also leverage unique funding programs. In 2022, National Institutes of Health (NIH) awarded 1,752 grants totaling $961 million represented for Houston. The Cancer Prevention and Research Institute of Texas (CPRIT) has also committed $6 billion in funding for groundbreaking cancer research, prevention and product development programs for companies located in Texas. Since its inception in 2009, CPRIT has awarded more than $3 billion in grants for cancer research, of which MD Anderson has received approximately 20 percent. 

Houston also has a growing number of life sciences developments that encourage innovation and collaboration between industry partners.

  • Generation Park, a 4,200-acre master-planned development, is creating a thriving ecosystem for companies to grow and provides a place where education and industry can converge. It will be the home of the San Jacinto Biotechnology Center, a biomanufacturing workforce institute that will offer certificate coursework in bioprocessing to students as part of a strategic partnership with the National Institute for Bioprocessing Research and Training (NIBRT).
  • TMC Helix Park is another life sciences development that will provide 6 million square feet of research labs, retail, hotel, and large scale commercialization space, in addition to TMC3, a collaborative research building with four founding institutions. According to the Real Deal, the University of Texas MD Anderson Cancer Center plans to build a $668 million laboratory expansion that will connect to TMC Helix Park. Construction is expected to begin in September, with completion estimated in late 2027.
  • Levit Green is a 53-acre mixed-use life sciences district under construction near Texas Medical Center that is expected to be completed this year. The initial five-story building will create 294,000 square feet of space overlooking a plaza and a man-made lake.
  • Texas A&M Innovation Plaza located in the Texas Medical Center is expected to be completed in 2024. Consisting of research facilities, affordable student housing, office space, retail space and parking, the Innovation Plaza will be home to the Texas A&M Engineering Medicine (EnMed) program and provide student housing for the Prairie View A&M University’s College of Nursing. This project is part of Houston's ongoing investment in programs that will grow the talent pipeline and prepare its future workforce.

The Partnership’s economic development team will be attending BIO International in Boston from June 5-8th to spotlight the region’s thriving life sciences ecosystem and its unique opportunities for innovation and growth.

Related News

Life Sciences

MD Anderson, Rice University Launch New Collaborative to Advance Cancer Research

7/2/24
A new collaboration between The University of Texas MD Anderson Cancer Center and Rice University promises to drive industry growth and advance life-saving technologies through the newly established Cancer Bioengineering Collaborative. The initiative will help foster collaboration between the two institutions on fundamental and translational cancer research, develop new technologies for cancer detection and therapy, and secure external funding in support of further research and training. Rice researcher and Cancer Prevention and Research Institute of Texas (CPRIT) scholar Gang Bao and MD Anderson’s Dr. Jeffrey Molldrem will lead the hub.  “From fundamental discoveries in cancer science, tumor immunology and patient care to innovative engineering advances in drug delivery systems, nanostructures and synthetic biology, there is great potential for enabling cross-disciplinary collaboration to develop new technologies and approaches for detecting, monitoring and treating cancer,” Molldrem, chair of Hematopoietic Biology & Malignancy at MD Anderson, said in a release. “Our goal is to bridge the gap between bioengineering and cancer research to create transformative solutions that significantly improve patient outcomes.” The collaborative will also host monthly seminars focused on cancer bioengineering, annual retreats to highlight research and international leaders in cancer and bioengineering. Five research areas will be at the core of the hub’s work: Cell therapies: Developing more effective cell-based immunotherapies, including chimeric antigen receptor- and T cell receptor-based approaches. Nanotechnologies: Using nanoparticles for targeted cancer detection and therapy. Cancer vaccines: Incorporating advanced biomaterials, synthetic biology and nanoparticle delivery systems to develop therapeutic cancer vaccines. Artificial intelligence: Leveraging advanced computing tools for high-precision analysis of samples to identify new targets and inform therapeutic design. Molecular imaging: Deploying advanced molecular imaging techniques to enhance diagnostic and therapeutic tools. A seed grant program will also be established to fund research projects in the early stages of development. The partnership between Rice and MD Anderson is a testament to how the greater Houston region is committed to advancing the life sciences and biotech industry. The region has seen major new life science developments come online recently, including Levit Green, TMC Helix Park and The Alexandria Center for Advanced Technologies in The Woodlands.   
Read More
Life Sciences

The Woodlands Innovation District Aims to Attract Life Sciences Companies

6/28/24
A new district in The Woodlands hopes to expand on the area’s resurgence in life sciences developments.    Post pandemic, life sciences companies have been establishing facilities in The Woodlands, particularly along Research Forest Drive. And now, Developers Howard Hughes and Vitrian are building upon that growth by adding an additional 86.3 acres for future development, aiming to attract more biomanufacturing companies to the area. The duo has dubbed the area The Woodlands Innovation District.  “This joint venture further diversifies the innovative industries that are represented in The Woodlands with the advancement of life science,” said Jim Carman, President of the Houston Region for The Howard Hughes Corporation in a statement. “The Woodlands continues to attract companies from a variety of industries seeking a highly-skilled talent pool, business-friendly environment, and high quality of life for their employees.”  The district joins the area’s cluster of existing life sciences companies, such as Millipore Sigma and VGXI. Cellipont Bioservices, a San Diego-based cell therapy contract development and manufacturing organization, recently opened a 76,000-square-foot facility in the area. The facility is dedicated to cell therapies and serves as the company's new headquarters.  Cellipont’s move to the greater Houston region, announced in 2022, kickstarted a surge in life sciences activity in The Woodlands. Bionova Scientific, another California-based biotech company, recently announced plans to expand into the area, with a 100,000-square-foot manufacturing and research facility. The company, which produces materials used by cancer-fighting cell therapy companies, is expected to begin operations at the new location in 2025.  Nearby, Nurix Therapeutics, a clinical-stage biopharmaceutical company based in San Francisco, has relocated to the Alexandria Center for Advanced Technologies. This 12-acre life sciences campus, formerly the Lexicon Pharmaceuticals site, was inaugurated last year with support from Lexicon’s Founder and CEO and now Nurix's Chief Executive Officer, Arthur Sands. Backed by California-based real estate firm Alexandria Real Estate Equities, the campus is still being built out, with the goal of becoming a smaller version of The Texas Medical Center.   These recent developments have established The Woodlands as a leader in life sciences in the region. According to CBRE’s 2023 U.S. Life Sciences Outlook, The Woodlands accounted for 60% of the Houston region’s life sciences lease transactions in 2022.  The Woodlands Innovation District will encompass five sites, each providing tenant facilities ranging from 40,000 to over 200,000 square feet. These sites will offer build-to-suit shell spaces, anticipated to be move-in ready by Spring 2025.  Learn more about Houston’s life sciences and biotechnology industries. 
Read More

Related Events

Economic Development

State of the Port

The Port of Houston is renowned as a strategic gateway to the world and plays a vital role in facilitating international trade and driving economic growth. As the nation’s largest port in foreign tonnage, Port…

Learn More
Learn More
Executive Partners